Milan, Italy

Gaetano Clavenna


Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 216(Granted Patents)


Location History:

  • Rho Milano, IT (1997)
  • Milan, IT (1986 - 1999)
  • L'Aquila, IT (2000)

Company Filing History:


Years Active: 1986-2000

Loading Chart...
11 patents (USPTO):Explore Patents

Title: Gaetano Clavenna: Innovator in Pharmaceutical Chemistry

Introduction

Gaetano Clavenna is a prominent inventor based in Milan, Italy, known for his significant contributions to pharmaceutical chemistry. With a total of 11 patents to his name, Clavenna has made remarkable advancements in the field, particularly in the development of novel pharmaceutical formulations.

Latest Patents

Among his latest patents, Clavenna has developed (R)-2-(3-benzoylphenyl) propionic acid salts and pharmaceutical preparations. This patent describes a new use of the enantiomer (R)-ketoprofen and its salts, which are beneficial in the therapy of neutrophil-dependent diseases and phlogistic processes. Additionally, he has worked on geminal carboxylic acids and esters thereof, which have shown antagonistic activity on osteoclast hyper-reactivity.

Career Highlights

Clavenna has had a successful career, working with notable companies such as Dompé Farmaceutici S.p.A. and Dompé S.p.A. His work has significantly impacted the pharmaceutical industry, leading to innovative treatments and formulations.

Collaborations

Throughout his career, Clavenna has collaborated with esteemed colleagues, including Gianfranco Caselli and Marco Mantovanini. These partnerships have fostered a collaborative environment that has enhanced the development of new pharmaceutical solutions.

Conclusion

Gaetano Clavenna's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor in the field. His work continues to pave the way for advancements in medical treatments and pharmaceutical formulations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…